智通财经APP讯,新锐医药(06108)发布截至2025年12月31日止年度全年业绩,收益约1.3亿港元,同比增加约38.9%。公司拥有人应占净亏损约为2010万港元,同比减少约35.2%。每股亏损11.94港仙。
公告称,净亏损减少主要由于并无2024财政年度录得的于接近到期日的滞销存货导致存货减值亏损约1310万港元;推广成本减少约210万港元;营销服务费减少约370万港元;及分销权预付款项摊销减少约210万港元(2024财政年度:约350万港元)。
智通财经APP讯,新锐医药(06108)发布截至2025年12月31日止年度全年业绩,收益约1.3亿港元,同比增加约38.9%。公司拥有人应占净亏损约为2010万港元,同比减少约35.2%。每股亏损11.94港仙。
公告称,净亏损减少主要由于并无2024财政年度录得的于接近到期日的滞销存货导致存货减值亏损约1310万港元;推广成本减少约210万港元;营销服务费减少约370万港元;及分销权预付款项摊销减少约210万港元(2024财政年度:约350万港元)。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.